Switching to an integrase inhibitor can raise diabetes risk in people with HIV
GLP-1 agonists could be a global game-changer, but need to be accessible and affordable
Most liver disease in people with HIV in low and middle-income countries is caused by metabolic disorders
Africa's health systems should urgently integrate HIV and co-morbidity services for older people with HIV
More evidence that integrase inhibitors don’t raise heart disease risk
Care for diabetes or high blood pressure can be delivered alongside HIV care in African clinics
Body mass index is sufficient to predict diabetes or metabolic syndrome, Italian study finds
Greater weight gain in first year of HIV treatment raises risks of diabetes, metabolic syndrome and precursors of heart disease
HIV is a “disease of shame” but diabetes is often harder to manage for African migrants in France
